Dermatology News

Cemiplimab provided clinically meaningful responses for patients with metastatic and locally advanced cutaneous squamous cell carcinoma, according to a study.

The 2024 election is one of the most consequential elections in recent history, and as physicians, we have a responsibility to vote.

A new laser system called focal point technology was able to deliver a high level of energy to the skin while avoiding sequelae, according to a study.

Adbry 300 mg/2 mL single-dose autoinjector is now available for the treatment of adults with moderate to severe atopic dermatitis in the U.S., LEO Pharma announced in a press release.

Most physicians and residents report feelings of burnout, while stigma about receiving mental health care remains prevalent, according to a new report from The Physicians Foundation.

Down regulation of fibrotic processes and upregulation of keratinocyte proliferation was associated with low-dose metformin in patients with central centrifugal cicatricial alopecia, or CCCA, according to a study.

Researchers confirmed that head and neck melanomas have distinct biological characteristics that make it more adverse to patients yet more responsive to immunotherapy, according to a study.

Published results showed that millennials saw heightened efficacy with prabotulinumtoxinA in the treatment of moderate to severe glabellar lines.

Pembrolizumab significantly extended OS at 10 years compared with ipilimumab for patients with advanced melanoma, according to study results presented at ESMO Congress.